SG11202004361SA - Quinazolinone compound and application thereof - Google Patents

Quinazolinone compound and application thereof

Info

Publication number
SG11202004361SA
SG11202004361SA SG11202004361SA SG11202004361SA SG11202004361SA SG 11202004361S A SG11202004361S A SG 11202004361SA SG 11202004361S A SG11202004361S A SG 11202004361SA SG 11202004361S A SG11202004361S A SG 11202004361SA SG 11202004361S A SG11202004361S A SG 11202004361SA
Authority
SG
Singapore
Prior art keywords
application
quinazolinone compound
quinazolinone
compound
Prior art date
Application number
SG11202004361SA
Other languages
English (en)
Inventor
Chengde Wu
Jingjie Huang
Tao Yu
Jiaqiang Dong
Tie-Lin Wang
Jie Li
Jian Li
Shuhui Chen
Original Assignee
Luoxin Pharmaceutical Shanghai Co Ltd
Shandong Luoxin Pharmaceutical Group Stock Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luoxin Pharmaceutical Shanghai Co Ltd, Shandong Luoxin Pharmaceutical Group Stock Co Ltd filed Critical Luoxin Pharmaceutical Shanghai Co Ltd
Publication of SG11202004361SA publication Critical patent/SG11202004361SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202004361SA 2017-11-13 2018-11-12 Quinazolinone compound and application thereof SG11202004361SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201711116253 2017-11-13
PCT/CN2018/115044 WO2019091476A1 (zh) 2017-11-13 2018-11-12 喹唑啉酮类化合物及其应用

Publications (1)

Publication Number Publication Date
SG11202004361SA true SG11202004361SA (en) 2020-06-29

Family

ID=66437577

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004361SA SG11202004361SA (en) 2017-11-13 2018-11-12 Quinazolinone compound and application thereof

Country Status (10)

Country Link
US (1) US20200317660A1 (ko)
EP (1) EP3712143A4 (ko)
JP (1) JP2021503447A (ko)
KR (1) KR20200088854A (ko)
CN (1) CN111344282A (ko)
AU (1) AU2018363482A1 (ko)
CA (1) CA3082499A1 (ko)
RU (1) RU2020119562A (ko)
SG (1) SG11202004361SA (ko)
WO (1) WO2019091476A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020228729A1 (zh) * 2019-05-13 2020-11-19 罗欣药业(上海)有限公司 喹唑啉酮类化合物的晶型及其制备方法
KR102329720B1 (ko) 2019-08-30 2021-11-23 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체
WO2022016420A1 (zh) * 2020-07-22 2022-01-27 罗欣药业(上海)有限公司 一种喹唑啉酮类化合物的晶型、其制备方法及应用
CN113461661B (zh) * 2021-07-12 2023-11-28 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 6-(吡啶-3-基)喹唑啉-4(3h)-酮类衍生物及其制备和应用
CN115703722B (zh) * 2021-08-03 2024-06-25 江苏国泰超威新材料有限公司 一种n,n-二甲基三氟甲基磺酰胺的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012087938A1 (en) * 2010-12-20 2012-06-28 Glaxosmithkline Llc Quinazolinone derivatives as antiviral agents
EP2968340A4 (en) * 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
US9216985B2 (en) * 2013-03-28 2015-12-22 Scifluor Life Sciences, Inc. 3-aryl-2-((arylamino)methyl)quinazolin-4-(3H)-ones
CN106458932A (zh) * 2014-06-13 2017-02-22 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂
CN108239067A (zh) * 2016-12-27 2018-07-03 沈阳药科大学 喹唑啉酮类衍生物及其制备方法和用途

Also Published As

Publication number Publication date
RU2020119562A (ru) 2021-12-16
CN111344282A (zh) 2020-06-26
JP2021503447A (ja) 2021-02-12
AU2018363482A1 (en) 2020-06-25
EP3712143A1 (en) 2020-09-23
KR20200088854A (ko) 2020-07-23
US20200317660A1 (en) 2020-10-08
CA3082499A1 (en) 2019-05-16
EP3712143A4 (en) 2021-04-14
WO2019091476A1 (zh) 2019-05-16

Similar Documents

Publication Publication Date Title
IL268190A (en) Quinazoline compound
IL273236A (en) Pyrazolopyrimidine compounds and their uses
HK1251547A1 (zh) 嘧啶或吡啶並吡啶酮類化合物及其應用
ZA201906135B (en) Tri-cycle compound and applications thereof
SG11202004361SA (en) Quinazolinone compound and application thereof
GB201714745D0 (en) New compounds and uses
GB201714740D0 (en) New compounds and uses
IL292488B1 (en) Pyridineamine-pyridone and pyrimidineamine-pyridone compounds
IL277502A (en) Compounds and uses for them
GB201714734D0 (en) New compounds and uses
IL279483A (en) Cyanotriazole compounds and their uses
GB201714736D0 (en) New compounds and uses
GB201712110D0 (en) New compounds and uses
IL269836B (en) Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use
IL292482B1 (en) Azaindolylpyridone and diazaindolylpyridone compounds
GB201700404D0 (en) Compounds and composistions
IL269843B (en) Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use
GB201720092D0 (en) New Compounds and uses
GB201719327D0 (en) New compounds and uses
GB201719233D0 (en) New compounds and uses
GB201714743D0 (en) New compounds and uses